Literature DB >> 9068520

Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation.

E Alt1, C Schmitt, R Ammer, A Plewan, F Evans, J Pasquantonio, T Ideker, G Lehmann, K Pütter, A Schömig.   

Abstract

The aim of this study was to evaluate the new method of low-energy, catheter-based intracardiac cardioversion in patients with chronic atrial fibrillation (AF) and to compare 2 different lead positions. Accordingly, we prospectively studied 80 consecutive patients with chronic AF (9.8 +/- 7.9 months) who were randomly assigned to undergo internal cardioversion either via defibrillation electrodes placed in the right atrium and coronary sinus (coronary sinus group) or via defibrillation electrodes placed in the right atrium and left pulmonary artery (pulmonary artery group). Intracardiac shocks were delivered by an external defibrillator synchronized to the QRS complex. After conversion, all patients were treated orally with sotalol (mean daily dose, 189 +/- 63 mg/day). For conversion to sinus rhythm, the overall mean energy requirement was 5.6 +/- 3.1 J. In the coronary sinus group, cardioversion was achieved in 35 of 38 patients at a mean energy level of 4.1 +/- 2.3 J (range 1.0 to 9.9), and in the pulmonary artery group in 39 of 42 patients with 7.2 +/- 3.1 J (range 2.5 to 14.8). Although there was no difference with regard to success rate, the energy differed significantly between the 2 groups (p < 0.01). Mean lead impedance was 56.4 +/- 7.0 omega and 54.6 +/- 8.5 omega, respectively (p = NS). No serious complications were observed in either lead group. At a mean follow-up of 14.2 +/- 7.0 months, 54% and 56%, respectively, of patients who had been converted successfully remained in sinus rhythm. Thus, low-energy biphasic shocks delivered between the right atrium and coronary sinus or pulmonary artery are equally effective for cardioversion of patients with chronic AF. The energy requirements for conversion from a pulmonary artery electrode position are higher than for the coronary sinus position.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9068520     DOI: 10.1016/s0002-9149(96)00827-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Clinical feasibility of low energy internal atrial cardioversion with a three-electrode configuration in patients with unsuccessful conventional configurations.

Authors:  G Benedini; A Gardini; T Toselli; G Antonioli; G Guardigli; G Saccomanno; M Marini
Journal:  J Interv Card Electrophysiol       Date:  2000-04       Impact factor: 1.900

Review 2.  Low-energy internal cardioversion of atrial fibrillation after failed external cardioversion: Texas Heart Institute experience and review of the literature.

Authors:  M Zaqqa; H Afshar; G R Khoshnevis; J A Lopez; A Massumi
Journal:  Tex Heart Inst J       Date:  1999

3.  A systematic evaluation of conventional and novel transvenous pathways for defibrillation.

Authors:  P R Roberts; S Allen; D C Smith; J F Urban; D E Euler; R W Dahl; M J Kallok; J M Morgan
Journal:  J Interv Card Electrophysiol       Date:  1999-10       Impact factor: 1.900

4.  Efficacy of a new balloon catheter for internal cardioversion of chronic atrial fibrillation without anaesthesia.

Authors:  E Alt; R Ammer; G Lehmann; C Schmitt; J Pasquantonio; A Schömig
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

5.  Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibrillation.

Authors:  Michalis Efremidis; Ioannis P Alexanian; Dimitrios Oikonomou; Dimitrios Manolatos; Konstantinos P Letsas; Loukas K Pappas; Gerasimos Gavrielatos; Maria Vadiaka; Constantinos C Mihas; Gerasimos S Filippatos; Antonios Sideris; Fotios Kardaras
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

6.  Current status of internal cardioversion in atrial fibrillation.

Authors:  Andreas Plewan; Eckhard Alt
Journal:  Indian Pacing Electrophysiol J       Date:  2002-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.